Insider Buying: Charles River Laboratories International, Inc. (NYSE:CRL) COO Acquires 1,514 Shares of Stock

Charles River Laboratories International, Inc. (NYSE:CRL) COO Birgit Girshick purchased 1,514 shares of Charles River Laboratories International stock in a transaction on Thursday, February 20th. The shares were acquired at an average cost of $164.63 per share, for a total transaction of $249,249.82. Following the completion of the transaction, the chief operating officer now owns 55,058 shares of the company’s stock, valued at $9,064,198.54. This represents a 2.83 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Charles River Laboratories International Stock Up 0.5 %

Shares of NYSE:CRL traded up $0.86 during midday trading on Friday, reaching $163.11. The company had a trading volume of 1,215,947 shares, compared to its average volume of 1,060,465. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.41 and a quick ratio of 1.14. The stock’s fifty day moving average price is $173.39 and its 200-day moving average price is $188.81. The stock has a market capitalization of $8.34 billion, a P/E ratio of 1,087.39, a PEG ratio of 6.77 and a beta of 1.37. Charles River Laboratories International, Inc. has a one year low of $150.79 and a one year high of $275.00.

Charles River Laboratories International (NYSE:CRL) last released its earnings results on Wednesday, February 19th. The medical research company reported $2.66 earnings per share for the quarter, beating the consensus estimate of $2.50 by $0.16. Charles River Laboratories International had a net margin of 0.52% and a return on equity of 14.69%. The firm had revenue of $1 billion during the quarter, compared to analyst estimates of $983.63 million. During the same quarter in the previous year, the firm earned $2.46 earnings per share. The firm’s revenue for the quarter was down 1.1% compared to the same quarter last year. Equities research analysts expect that Charles River Laboratories International, Inc. will post 9.41 earnings per share for the current fiscal year.

Institutional Trading of Charles River Laboratories International

Institutional investors have recently added to or reduced their stakes in the business. Versant Capital Management Inc increased its stake in Charles River Laboratories International by 1,071.4% during the fourth quarter. Versant Capital Management Inc now owns 164 shares of the medical research company’s stock valued at $30,000 after purchasing an additional 150 shares during the last quarter. Assetmark Inc. increased its stake in Charles River Laboratories International by 1,153.3% during the third quarter. Assetmark Inc. now owns 188 shares of the medical research company’s stock valued at $37,000 after purchasing an additional 173 shares during the last quarter. Pinnacle Bancorp Inc. increased its stake in Charles River Laboratories International by 52.0% during the fourth quarter. Pinnacle Bancorp Inc. now owns 190 shares of the medical research company’s stock valued at $35,000 after purchasing an additional 65 shares during the last quarter. Optiver Holding B.V. bought a new stake in Charles River Laboratories International during the fourth quarter valued at $37,000. Finally, GeoWealth Management LLC boosted its holdings in shares of Charles River Laboratories International by 311.5% during the fourth quarter. GeoWealth Management LLC now owns 251 shares of the medical research company’s stock valued at $46,000 after acquiring an additional 190 shares during the period. Institutional investors own 98.91% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have recently issued reports on CRL shares. Evercore ISI lifted their price objective on shares of Charles River Laboratories International from $190.00 to $225.00 and gave the company an “in-line” rating in a research note on Thursday, November 7th. William Blair lowered shares of Charles River Laboratories International from an “outperform” rating to a “market perform” rating in a research note on Wednesday, January 22nd. Robert W. Baird dropped their price objective on shares of Charles River Laboratories International from $177.00 to $173.00 and set a “neutral” rating on the stock in a research note on Thursday. CLSA lowered shares of Charles River Laboratories International from a “hold” rating to an “underperform” rating and set a $164.00 price objective on the stock. in a research note on Monday, November 18th. Finally, Morgan Stanley dropped their price objective on shares of Charles River Laboratories International from $220.00 to $184.00 and set an “equal weight” rating on the stock in a research note on Wednesday, February 5th. Three equities research analysts have rated the stock with a sell rating, thirteen have issued a hold rating and one has assigned a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Hold” and an average target price of $195.71.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).